2020 ICD-10-CM Diagnosis Code C92.0

Acute myeloblastic leukemia

    2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
  • C92.0 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2020 edition of ICD-10-CM C92.0 became effective on October 1, 2019.
  • This is the American ICD-10-CM version of C92.0 - other international versions of ICD-10 C92.0 may differ.
Applicable To
  • Acute myeloblastic leukemia, minimal differentiation
  • Acute myeloblastic leukemia (with maturation)
  • Acute myeloblastic leukemia 1/ETO
  • Acute myeloblastic leukemia M0
  • Acute myeloblastic leukemia M1
  • Acute myeloblastic leukemia M2
  • Acute myeloblastic leukemia with t(8;21)
  • Acute myeloblastic leukemia (without a FAB classification) NOS
  • Refractory anemia with excess blasts in transformation [RAEB T]
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C92.0. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • acute exacerbation of chronic myeloid leukemia (
    ICD-10-CM Diagnosis Code C92.10

    Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission

      2016 2017 2018 2019 2020 Billable/Specific Code
    Applicable To
    • Chronic myeloid leukemia, BCR/ABL-positive with failed remission
    • Chronic myeloid leukemia, BCR/ABL-positive NOS
  • refractory anemia with excess of blasts not in transformation (
    ICD-10-CM Diagnosis Code D46.2

    Refractory anemia with excess of blasts [RAEB]

      2016 2017 - Revised Code 2018 2019 2020 Non-Billable/Non-Specific Code
The following code(s) above C92.0 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C92.0:
  • C00-D49
    2020 ICD-10-CM Range C00-D49


    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
  • C81-C96
    2020 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
  • C92
    ICD-10-CM Diagnosis Code C92

    Myeloid leukemia

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    • granulocytic leukemia
    • myelogenous leukemia
    Type 1 Excludes
    • personal history of leukemia (Z85.6)
    Myeloid leukemia
Clinical Information
  • A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (amls) encompasses four major categories: 1) aml with recurrent genetic abnormalities 2) aml with multilineage dysplasia 3) therapy-related aml 4) aml not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of aml has been recently reduced from 30% (french-american-british [fab] classification) to 20% (who classification). (who, 2001)
  • A quickly progressing disease in which too many immature blood-forming cells are found in the blood and bone marrow.
  • Acute leukemia arising from myeloid tissue in which the granular, polymorphonuclear leukocytes and their precursors predominate.
  • An acute myeloid leukemia (aml) characterized by blasts with evidence of maturation to more mature neutrophils. Patients often present with anemia, neutropenia, and thrombocytopenia. Aml with the t(8;21) is usually aml with maturation. This type of aml frequently responds to aggressive therapy. (who, 2001)
  • An acute myeloid leukemia (aml) characterized by blasts without evidence of maturation to more mature neutrophils. The patients present with anemia, neutropenia, and thrombocytopenia. This type of aml usually follows an aggressive clinical course. (who, 2001)
  • An acute myeloid leukemia (aml) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. The myeloid origin of the blasts is demonstrated by immunohistochemistry and/or electron microscopic studies. The patients present with anemia, neutropenia, and thrombocytopenia. The prognosis is usually poor. (who, 2001)
  • An aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood.
  • Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce neutrophils; basophils; eosinophils; and monocytes.
  • Leukemia commonly occurring after alkylating agent treatment; manifestations include pancytopenia, megaloblastic bone marrow, and nucleated red cells in peripheral marrow; patients usually have chromosomal abnormalities in marrow cells.
  • leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (aml), there are too many of a specific type of white blood cell called a myeloblast.aml is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of aml include:
    • fever
    • shortness of breath
    • easy bruising or bleeding
    • bleeding under the skin
    • weakness or feeling tired
    • weight loss or loss of appetite
    tests that examine the blood and bone marrow diagnose aml. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted immune therapy. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. nih: national cancer institute
  • Refractory anemia with excess blasts in transformation (raeb-t) is characterised by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood. The peripheral blood blast count ranges from 20% to 30%. Raeb-t used to be a subcategory of myelodysplastic syndromes in the past. Recently, the term has been eliminated from the who based classification of myelodysplastic syndromes. The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%. The elimination of the raeb-t term by the who experts has created confusion and ongoing arguments. Currently, according to who classification, the vast majority of raeb-t cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome). A minority of cases are part of raeb-2.
  • This term refers to acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. It includes entities classified according to the french-american-british classification scheme.
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
Code annotations containing back-references to C92.0:
  • Type 1 Excludes: D64
    ICD-10-CM Diagnosis Code D64

    Other anemias

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • refractory anemia (D46.-)
    • refractory anemia with excess blasts in transformation [RAEB T] (C92.0-)

Diagnosis Index entries containing back-references to C92.0:
  • Leukemia, leukemic C95.9-
    ICD-10-CM Diagnosis Code C95.9-

    Leukemia, unspecified

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    • acute myeloid, NOS C92.0-
    • myeloid C92.9-
      ICD-10-CM Diagnosis Code C92.9-

      Myeloid leukemia, unspecified

        2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
      • acute C92.0-
    • acute myeloblastic C92.0- (minimal differentiation) (with maturation)
    • AML C92.0- (1/ETO) (M0) (M1) (M2) (without a FAB classification)
  • Myelosis
    • acute C92.0-

ICD-10-CM Codes Adjacent To C92.0
C91.A2 …… in relapse
C91.Z Other lymphoid leukemia
C91.Z0 …… not having achieved remission
C91.Z1 …… in remission
C91.Z2 …… in relapse
C91.9 Lymphoid leukemia, unspecified
C91.90 …… not having achieved remission
C91.91 …… in remission
C91.92 …… in relapse
C92 Myeloid leukemia
C92.0 Acute myeloblastic leukemia
C92.00 …… not having achieved remission
C92.01 …… in remission
C92.02 …… in relapse
C92.1 Chronic myeloid leukemia, BCR/ABL-positive
C92.10 …… not having achieved remission
C92.11 …… in remission
C92.12 …… in relapse
C92.2 Atypical chronic myeloid leukemia, BCR/ABL-negative
C92.20 …… not having achieved remission
C92.21 …… in remission

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.